CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A strong index level often signals robust momentum and potential persistence. Interpret carefully to adjust positions and risk exposure.
24,666 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Among a long list of there ultra-high-yield dividend stocks, two stand out for safety and consistent income. Learn wh...
If you own rental real estate, you’ve probably wondered how to boost cash flow without waiting years for upside. A co...
When a veteran value investor piles into a beaten-down name, traders take notice. Prem Watsa recently added to his Un...
An insider sale at Grindr has traders buzzing. This article breaks down what this grindr insider trade signals for lo...
Gas costs have surged amid renewed Middle East tensions, with drivers now paying more than before. Analysts warn vola...
As Washington returns from recess, Bitcoin's recovery tests resolve ahead of a pivotal vote on the Digital Asset Mark...
In a market fixated on the giants, Rezolve AI is flying under the radar as it grows ARR and eyes profitability in the...
The VIX eased toward the mid-20s as equities edged higher and oil spiked on geopolitical tensions. Analysts say the m...
A landmark $1.5 billion bet on counter-drone tech sets Motorola Solutions up for deeper public-safety leadership. Her...
Healthcare fraud hits your wallet. This piece explains a real case where a lab owner allegedly billed Medicaid for te...
A Parabilis Medicines director recently disclosed a substantial stake just after the company’s fresh IPO. This articl...